Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 764

1.

Phase I trial of belinostat in combination with 13-cis-retinoic acid in advanced solid tumor malignancies: a California Cancer Consortium NCI/CTEP sponsored trial.

Luu T, Frankel P, Beumer JH, Lim D, Cristea M, Appleman LJ, Lenz HJ, Gandara DR, Kiesel BF, Piekarz RL, Newman EM.

Cancer Chemother Pharmacol. 2019 Sep 14. doi: 10.1007/s00280-019-03955-7. [Epub ahead of print]

PMID:
31522242
2.

Partition: a surjective mapping approach for dimensionality reduction.

Millstein J, Battaglin F, Barrett M, Cao S, Zhang W, Stintzing S, Heinemann V, Lenz HJ.

Bioinformatics. 2019 Aug 26. pii: btz661. doi: 10.1093/bioinformatics/btz661. [Epub ahead of print]

PMID:
31504178
3.

Associations of Physical Activity With Survival and Progression in Metastatic Colorectal Cancer: Results From Cancer and Leukemia Group B (Alliance)/SWOG 80405.

Guercio BJ, Zhang S, Ou FS, Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, O'Neil BH, Shaw JE, Polite BN, Hochster HS, Atkins JN, Goldberg RM, Sato K, Ng K, Van Blarigan E, Mayer RJ, Blanke CD, O'Reilly EM, Fuchs CS, Meyerhardt JA.

J Clin Oncol. 2019 Aug 13:JCO1901019. doi: 10.1200/JCO.19.01019. [Epub ahead of print]

PMID:
31408415
4.

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer.

Battaglin F, Puccini A, Ahcene Djaballah S, Lenz HJ.

Cancer Manag Res. 2019 Jun 28;11:5911-5924. doi: 10.2147/CMAR.S186042. eCollection 2019.

5.

The safety and efficacy of trifluridine-tipiracil for metastatic colorectal cancer: A pharmacy perspective.

Chan BM, Hochster HS, Lenz HJ.

Am J Health Syst Pharm. 2019 Feb 21;76(6):339-348. doi: 10.1093/ajhp/zxy006.

PMID:
31361848
6.

Osteoporosis in colorectal cancer survivors: analysis of the linkage between SWOG trial enrollees and Medicare claims.

Barzi A, Hershman DL, Till C, Barlow WE, Ramsey S, Lenz HJ, Hochster HS, Unger JM.

Arch Osteoporos. 2019 Jul 28;14(1):83. doi: 10.1007/s11657-019-0629-7.

PMID:
31352608
7.

A phase 1b dose escalation study of Wnt pathway inhibitor vantictumab in combination with nab-paclitaxel and gemcitabine in patients with previously untreated metastatic pancreatic cancer.

Davis SL, Cardin DB, Shahda S, Lenz HJ, Dotan E, O'Neil BH, Kapoun AM, Stagg RJ, Berlin J, Messersmith WA, Cohen SJ.

Invest New Drugs. 2019 Jul 23. doi: 10.1007/s10637-019-00824-1. [Epub ahead of print]

PMID:
31338636
8.

Aryl hydrocarbon receptor nuclear translocator-like (ARNTL/BMAL1) is associated with bevacizumab resistance in colorectal cancer via regulation of vascular endothelial growth factor A.

Burgermeister E, Battaglin F, Eladly F, Wu W, Herweck F, Schulte N, Betge J, Härtel N, Kather JN, Weis CA, Gaiser T, Marx A, Weiss C, Hofheinz R, Miller IS, Loupakis F, Lenz HJ, Byrne AT, Ebert MP.

EBioMedicine. 2019 Jul;45:139-154. doi: 10.1016/j.ebiom.2019.07.004. Epub 2019 Jul 9.

9.

High thymidylate synthase gene expression predicts poor outcome after resection of hepatocellular carcinoma.

Donner DB, Nakakura EK, Venook AP, Lenz HJ, Zhang W, Hwang J, Bergsland EK, Lin MH, Toriguchi K, Antonia RJ, Warren RS.

PLoS One. 2019 Jul 10;14(7):e0219469. doi: 10.1371/journal.pone.0219469. eCollection 2019.

10.

A phase I pharmacokinetic study of belinostat in patients with advanced cancers and varying degrees of liver dysfunction.

Takebe N, Beumer JH, Kummar S, Kiesel BF, Dowlati A, O'Sullivan Coyne G, Piekarz R, Rubinstein L, Fogli LK, Vaishampayan U, Goel S, O'Bryant CL, El-Rayes BF, Chung V, Lenz HJ, Kim R, Belani CP, Tuscano JM, Schelman W, Moore N, Doroshow JH, Chen AP.

Br J Clin Pharmacol. 2019 Jul 4. doi: 10.1111/bcp.14054. [Epub ahead of print]

PMID:
31271459
11.

Reply to S. Sorscher.

Innocenti F, Ou FS, Qu X, Zemla T, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O.

J Clin Oncol. 2019 Sep 1;37(25):2291-2293. doi: 10.1200/JCO.19.01366. Epub 2019 Jul 3. No abstract available.

PMID:
31268798
12.

Regorafenib dose-optimisation in patients with refractory metastatic colorectal cancer (ReDOS): a randomised, multicentre, open-label, phase 2 study.

Bekaii-Saab TS, Ou FS, Ahn DH, Boland PM, Ciombor KK, Heying EN, Dockter TJ, Jacobs NL, Pasche BC, Cleary JM, Meyers JP, Desnoyers RJ, McCune JS, Pedersen K, Barzi A, Chiorean EG, Sloan J, Lacouture ME, Lenz HJ, Grothey A.

Lancet Oncol. 2019 Aug;20(8):1070-1082. doi: 10.1016/S1470-2045(19)30272-4. Epub 2019 Jun 28.

PMID:
31262657
13.

Quantitative evidence for early metastatic seeding in colorectal cancer.

Hu Z, Ding J, Ma Z, Sun R, Seoane JA, Scott Shaffer J, Suarez CJ, Berghoff AS, Cremolini C, Falcone A, Loupakis F, Birner P, Preusser M, Lenz HJ, Curtis C.

Nat Genet. 2019 Jul;51(7):1113-1122. doi: 10.1038/s41588-019-0423-x. Epub 2019 Jun 17.

PMID:
31209394
14.

Conversations About Financial Issues in Routine Oncology Practices: A Multicenter Study.

Warsame R, Kennedy CC, Kumbamu A, Branda M, Fernandez C, Kimball B, Leppin AL, O'Byrne T, Jatoi A, Lenz HJ, Tilburt JC.

J Oncol Pract. 2019 Aug;15(8):e690-e703. doi: 10.1200/JOP.18.00618. Epub 2019 Jun 4.

PMID:
31162996
15.

Safety of Nivolumab plus Low-Dose Ipilimumab in Previously Treated Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer.

Morse MA, Overman MJ, Hartman L, Khoukaz T, Brutcher E, Lenz HJ, Atasoy A, Shangguan T, Zhao H, El-Rayes B.

Oncologist. 2019 May 30. pii: theoncologist.2019-0129. doi: 10.1634/theoncologist.2019-0129. [Epub ahead of print]

PMID:
31147488
16.

The current state of molecular testing in the treatment of patients with solid tumors, 2019.

El-Deiry WS, Goldberg RM, Lenz HJ, Shields AF, Gibney GT, Tan AR, Brown J, Eisenberg B, Heath EI, Phuphanich S, Kim E, Brenner AJ, Marshall JL.

CA Cancer J Clin. 2019 Jul;69(4):305-343. doi: 10.3322/caac.21560. Epub 2019 May 22. Review.

17.

A Multicenter Comparison of Complementary and Alternative Medicine (CAM) Discussions in Oncology Care: The Role of Time, Patient-Centeredness, and Practice Context.

Tilburt J, Yost KJ, Lenz HJ, Zúñiga ML, O'Byrne T, Branda ME, Leppin AL, Kimball B, Fernandez C, Jatoi A, Barwise A, Kumbamu A, Montori V, Koenig BA, Geller G, Larson S, Roter DL.

Oncologist. 2019 May 17. pii: theoncologist.2019-0093. doi: 10.1634/theoncologist.2019-0093. [Epub ahead of print]

PMID:
31101701
18.

Impact of Consensus Molecular Subtype on Survival in Patients With Metastatic Colorectal Cancer: Results From CALGB/SWOG 80405 (Alliance).

Lenz HJ, Ou FS, Venook AP, Hochster HS, Niedzwiecki D, Goldberg RM, Mayer RJ, Bertagnolli MM, Blanke CD, Zemla T, Qu X, Wirapati P, Tejpar S, Innocenti F, Kabbarah O.

J Clin Oncol. 2019 Aug 1;37(22):1876-1885. doi: 10.1200/JCO.18.02258. Epub 2019 May 1.

PMID:
31042420
19.

A phase 1b study evaluating the safety and pharmacokinetics of regorafenib in combination with cetuximab in patients with advanced solid tumors.

Weekes C, Lockhart AC, Lee JJ, Sturm I, Cleton A, Huang F, Lenz HJ.

Int J Cancer. 2019 Nov 1;145(9):2450-2458. doi: 10.1002/ijc.32317. Epub 2019 Jun 14.

PMID:
30958892
20.

Mutational Analysis of Patients With Colorectal Cancer in CALGB/SWOG 80405 Identifies New Roles of Microsatellite Instability and Tumor Mutational Burden for Patient Outcome.

Innocenti F, Ou FS, Qu X, Zemla TJ, Niedzwiecki D, Tam R, Mahajan S, Goldberg RM, Bertagnolli MM, Blanke CD, Sanoff H, Atkins J, Polite B, Venook AP, Lenz HJ, Kabbarah O.

J Clin Oncol. 2019 May 10;37(14):1217-1227. doi: 10.1200/JCO.18.01798. Epub 2019 Mar 13.

PMID:
30865548
21.

AMPK variant, a candidate of novel predictor for chemotherapy in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC and FIRE3.

Tokunaga R, Cao S, Naseem M, Battaglin F, Lo JH, Arai H, Loupakis F, Stintzing S, Puccini A, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ.

Int J Cancer. 2019 Oct 15;145(8):2082-2090. doi: 10.1002/ijc.32261. Epub 2019 Mar 26.

PMID:
30856283
22.

Impact of polymorphisms within genes involved in regulating DNA methylation in patients with metastatic colorectal cancer enrolled in three independent, randomised, open-label clinical trials: a meta-analysis from TRIBE, MAVERICC and FIRE-3.

Puccini A, Loupakis F, Stintzing S, Cao S, Battaglin F, Togunaka R, Naseem M, Berger MD, Soni S, Zhang W, Mancao C, Salhia B, Mumenthaler SM, Weisenberger DJ, Liang G, Cremolini C, Heinemann V, Falcone A, Millstein J, Lenz HJ.

Eur J Cancer. 2019 Apr;111:138-147. doi: 10.1016/j.ejca.2019.01.105. Epub 2019 Mar 7.

PMID:
30852420
23.

Language Matters: Development of an Objective Structured Language Test for Foreign Physicians - Results of a Pilot Study in Germany.

Lenz H, Opitz A, Huber D, Jacobs F, Paik WG, Roche J, Fischer MR.

GMS J Med Educ. 2019 Feb 15;36(1):Doc2. doi: 10.3205/zma001210. eCollection 2019.

24.

Molecular Profiling of Appendiceal Adenocarcinoma and Comparison with Right-sided and Left-sided Colorectal Cancer.

Tokunaga R, Xiu J, Johnston C, Goldberg RM, Philip PA, Seeber A, Naseem M, Lo JH, Arai H, Battaglin F, Puccini A, Berger MD, Soni S, Zhang W, Hwang JJ, Shields AF, Marshall JL, Baba H, Korn WM, Lenz HJ.

Clin Cancer Res. 2019 May 15;25(10):3096-3103. doi: 10.1158/1078-0432.CCR-18-3388. Epub 2019 Jan 28.

PMID:
30692096
25.

Shared heritability and functional enrichment across six solid cancers.

Jiang X, Finucane HK, Schumacher FR, Schmit SL, Tyrer JP, Han Y, Michailidou K, Lesseur C, Kuchenbaecker KB, Dennis J, Conti DV, Casey G, Gaudet MM, Huyghe JR, Albanes D, Aldrich MC, Andrew AS, Andrulis IL, Anton-Culver H, Antoniou AC, Antonenkova NN, Arnold SM, Aronson KJ, Arun BK, Bandera EV, Barkardottir RB, Barnes DR, Batra J, Beckmann MW, Benitez J, Benlloch S, Berchuck A, Berndt SI, Bickeböller H, Bien SA, Blomqvist C, Boccia S, Bogdanova NV, Bojesen SE, Bolla MK, Brauch H, Brenner H, Brenton JD, Brook MN, Brunet J, Brunnström H, Buchanan DD, Burwinkel B, Butzow R, Cadoni G, Caldés T, Caligo MA, Campbell I, Campbell PT, Cancel-Tassin G, Cannon-Albright L, Campa D, Caporaso N, Carvalho AL, Chan AT, Chang-Claude J, Chanock SJ, Chen C, Christiani DC, Claes KBM, Claessens F, Clements J, Collée JM, Correa MC, Couch FJ, Cox A, Cunningham JM, Cybulski C, Czene K, Daly MB, deFazio A, Devilee P, Diez O, Gago-Dominguez M, Donovan JL, Dörk T, Duell EJ, Dunning AM, Dwek M, Eccles DM, Edlund CK, Edwards DRV, Ellberg C, Evans DG, Fasching PA, Ferris RL, Liloglou T, Figueiredo JC, Fletcher O, Fortner RT, Fostira F, Franceschi S, Friedman E, Gallinger SJ, Ganz PA, Garber J, García-Sáenz JA, Gayther SA, Giles GG, Godwin AK, Goldberg MS, Goldgar DE, Goode EL, Goodman MT, Goodman G, Grankvist K, Greene MH, Gronberg H, Gronwald J, Guénel P, Håkansson N, Hall P, Hamann U, Hamdy FC, Hamilton RJ, Hampe J, Haugen A, Heitz F, Herrero R, Hillemanns P, Hoffmeister M, Høgdall E, Hong YC, Hopper JL, Houlston R, Hulick PJ, Hunter DJ, Huntsman DG, Idos G, Imyanitov EN, Ingles SA, Isaacs C, Jakubowska A, James P, Jenkins MA, Johansson M, Johansson M, John EM, Joshi AD, Kaneva R, Karlan BY, Kelemen LE, Kühl T, Khaw KT, Khusnutdinova E, Kibel AS, Kiemeney LA, Kim J, Kjaer SK, Knight JA, Kogevinas M, Kote-Jarai Z, Koutros S, Kristensen VN, Kupryjanczyk J, Lacko M, Lam S, Lambrechts D, Landi MT, Lazarus P, Le ND, Lee E, Lejbkowicz F, Lenz HJ, Leslie G, Lessel D, Lester J, Levine DA, Li L, Li CI, Lindblom A, Lindor NM, Liu G, Loupakis F, Lubiński J, Maehle L, Maier C, Mannermaa A, Marchand LL, Margolin S, May T, McGuffog L, Meindl A, Middha P, Miller A, Milne RL, MacInnis RJ, Modugno F, Montagna M, Moreno V, Moysich KB, Mucci L, Muir K, Mulligan AM, Nathanson KL, Neal DE, Ness AR, Neuhausen SL, Nevanlinna H, Newcomb PA, Newcomb LF, Nielsen FC, Nikitina-Zake L, Nordestgaard BG, Nussbaum RL, Offit K, Olah E, Olama AAA, Olopade OI, Olshan AF, Olsson H, Osorio A, Pandha H, Park JY, Pashayan N, Parsons MT, Pejovic T, Penney KL, Peters WHM, Phelan CM, Phipps AI, Plaseska-Karanfilska D, Pring M, Prokofyeva D, Radice P, Stefansson K, Ramus SJ, Raskin L, Rennert G, Rennert HS, van Rensburg EJ, Riggan MJ, Risch HA, Risch A, Roobol MJ, Rosenstein BS, Rossing MA, De Ruyck K, Saloustros E, Sandler DP, Sawyer EJ, Schabath MB, Schleutker J, Schmidt MK, Setiawan VW, Shen H, Siegel EM, Sieh W, Singer CF, Slattery ML, Sorensen KD, Southey MC, Spurdle AB, Stanford JL, Stevens VL, Stintzing S, Stone J, Sundfeldt K, Sutphen R, Swerdlow AJ, Tajara EH, Tangen CM, Tardon A, Taylor JA, Teare MD, Teixeira MR, Terry MB, Terry KL, Thibodeau SN, Thomassen M, Bjørge L, Tischkowitz M, Toland AE, Torres D, Townsend PA, Travis RC, Tung N, Tworoger SS, Ulrich CM, Usmani N, Vachon CM, Van Nieuwenhuysen E, Vega A, Aguado-Barrera ME, Wang Q, Webb PM, Weinberg CR, Weinstein S, Weissler MC, Weitzel JN, West CML, White E, Whittemore AS, Wichmann HE, Wiklund F, Winqvist R, Wolk A, Woll P, Woods M, Wu AH, Wu X, Yannoukakos D, Zheng W, Zienolddiny S, Ziogas A, Zorn KK, Lane JM, Saxena R, Thomas D, Hung RJ, Diergaarde B, McKay J, Peters U, Hsu L, García-Closas M, Eeles RA, Chenevix-Trench G, Brennan PJ, Haiman CA, Simard J, Easton DF, Gruber SB, Pharoah PDP, Price AL, Pasaniuc B, Amos CI, Kraft P, Lindström S.

Nat Commun. 2019 Jan 25;10(1):431. doi: 10.1038/s41467-018-08054-4.

26.

Safety and Tolerability of c-MET Inhibitors in Cancer.

Puccini A, Marín-Ramos NI, Bergamo F, Schirripa M, Lonardi S, Lenz HJ, Loupakis F, Battaglin F.

Drug Saf. 2019 Feb;42(2):211-233. doi: 10.1007/s40264-018-0780-x. Review.

PMID:
30649748
27.

What Should We Do Better? Lessons from Negative Results of a Biomarker Validation Study.

Battaglin F, Lenz HJ.

J Natl Cancer Inst. 2019 Jan 14. doi: 10.1093/jnci/djy217. [Epub ahead of print] No abstract available.

PMID:
30649462
28.

An equal opportunity for everyone?! Supporting international students of medicine at the Ludwig-Maximilians-University in Munich.

Lenz H, Paik WG, Jacobs F.

GMS J Med Educ. 2018 Nov 30;35(5):Doc55. doi: 10.3205/zma001201. eCollection 2018.

29.

Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial.

Suenaga M, Stintzing S, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Heinemann V, Lenz HJ.

Eur J Cancer. 2019 Jan;107:100-114. doi: 10.1016/j.ejca.2018.11.019. Epub 2018 Dec 14.

PMID:
30554073
30.

Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).

Hurwitz HI, Tan BR, Reeves JA, Xiong H, Somer B, Lenz HJ, Hochster HS, Scappaticci F, Palma JF, Price R, Lee JJ, Nicholas A, Sommer N, Bendell J.

Oncologist. 2019 Jul;24(7):921-932. doi: 10.1634/theoncologist.2018-0344. Epub 2018 Dec 14.

PMID:
30552157
31.

B cell and B cell-related pathways for novel cancer treatments.

Tokunaga R, Naseem M, Lo JH, Battaglin F, Soni S, Puccini A, Berger MD, Zhang W, Baba H, Lenz HJ.

Cancer Treat Rev. 2019 Feb;73:10-19. doi: 10.1016/j.ctrv.2018.12.001. Epub 2018 Dec 3. Review.

PMID:
30551036
32.

Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives.

Battaglin F, Naseem M, Lenz HJ, Salem ME.

Clin Adv Hematol Oncol. 2018 Nov;16(11):735-745. Review.

PMID:
30543589
33.

Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.

Loupakis F, Hurwitz HI, Saltz L, Arnold D, Grothey A, Nguyen QL, Osborne S, Talbot J, Srock S, Lenz HJ.

Br J Cancer. 2018 Dec;119(12):1451-1455. doi: 10.1038/s41416-018-0304-6. Epub 2018 Nov 29.

34.

Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity.

Cheng Q, Shi X, Han M, Smbatyan G, Lenz HJ, Zhang Y.

J Am Chem Soc. 2018 Dec 5;140(48):16413-16417. doi: 10.1021/jacs.8b10047. Epub 2018 Nov 19.

PMID:
30452238
35.

Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients.

Suenaga M, Cao S, Zhang W, Yang D, Ning Y, Okazaki S, Berger MD, Miyamoto Y, Schirripa M, Soni S, Barzi A, Yamaguchi T, Lenz HJ.

Int J Cancer. 2019 May 15;144(10):2567-2577. doi: 10.1002/ijc.31968. Epub 2018 Dec 14.

PMID:
30411783
36.

Management of Advanced Small Bowel Cancer.

Puccini A, Battaglin F, Lenz HJ.

Curr Treat Options Oncol. 2018 Nov 5;19(12):69. doi: 10.1007/s11864-018-0592-3. Review.

PMID:
30397729
37.

Prognostic Effect of Adenosine-related Genetic Variants in Metastatic Colorectal Cancer Treated With Bevacizumab-based Chemotherapy.

Tokunaga R, Cao S, Naseem M, Lo JH, Battaglin F, Puccini A, Berger MD, Soni S, Millstein J, Zhang W, Stintzing S, Loupakis F, Cremolini C, Heinemann V, Falcone A, Lenz HJ.

Clin Colorectal Cancer. 2019 Mar;18(1):e8-e19. doi: 10.1016/j.clcc.2018.09.003. Epub 2018 Sep 13.

PMID:
30293873
38.

Tumor Sidedness and Enriched Gene Groups for Efficacy of First-line Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Mogushi K, Lenz HJ, Zhang W, Tsuji A, Takahashi T, Denda T, Shimada K, Kochi M, Nakamura M, Kotaka M, Segawa Y, Tanioka H, Negoro Y, Moran M, Astrow SH, Hsiang J, Stephens C, Fujii M, Ichikawa W.

Mol Cancer Ther. 2018 Dec;17(12):2788-2795. doi: 10.1158/1535-7163.MCT-18-0694. Epub 2018 Oct 1.

PMID:
30275242
39.

MAVERICC, a Randomized, Biomarker-stratified, Phase II Study of mFOLFOX6-Bevacizumab versus FOLFIRI-Bevacizumab as First-line Chemotherapy in Metastatic Colorectal Cancer.

Parikh AR, Lee FC, Yau L, Koh H, Knost J, Mitchell EP, Bosanac I, Choong N, Scappaticci F, Mancao C, Lenz HJ.

Clin Cancer Res. 2019 May 15;25(10):2988-2995. doi: 10.1158/1078-0432.CCR-18-1221. Epub 2018 Sep 17.

PMID:
30224341
40.

Immune-related Genes to Dominate Neutrophil-lymphocyte Ratio (NLR) Associated With Survival of Cetuximab Treatment in Metastatic Colorectal Cancer.

Sunakawa Y, Yang D, Cao S, Zhang W, Moran M, Astrow SH, Hsiang J, Stephens C, Tsuji A, Takahashi T, Tanioka H, Negoro Y, Takagane A, Tani S, Yamaguchi T, Eto T, Fujii M, Ichikawa W, Lenz HJ.

Clin Colorectal Cancer. 2018 Dec;17(4):e741-e749. doi: 10.1016/j.clcc.2018.08.002. Epub 2018 Aug 23.

PMID:
30219280
41.

Self-associated molecular patterns mediate cancer immune evasion by engaging Siglecs on T cells.

Stanczak MA, Siddiqui SS, Trefny MP, Thommen DS, Boligan KF, von Gunten S, Tzankov A, Tietze L, Lardinois D, Heinzelmann-Schwarz V, von Bergwelt-Baildon M, Zhang W, Lenz HJ, Han Y, Amos CI, Syedbasha M, Egli A, Stenner F, Speiser DE, Varki A, Zippelius A, Läubli H.

J Clin Invest. 2018 Nov 1;128(11):4912-4923. doi: 10.1172/JCI120612. Epub 2018 Sep 24.

42.

Impact of Patient Age on Molecular Alterations of Left-Sided Colorectal Tumors.

Puccini A, Lenz HJ, Marshall JL, Arguello D, Raghavan D, Korn WM, Weinberg BA, Poorman K, Heeke AL, Philip PA, Shields AF, Goldberg RM, Salem ME.

Oncologist. 2019 Mar;24(3):319-326. doi: 10.1634/theoncologist.2018-0117. Epub 2018 Jul 17.

PMID:
30018131
43.

Nintedanib for the treatment of patients with refractory metastatic colorectal cancer (LUME-Colon 1): a phase III, international, randomized, placebo-controlled study.

Van Cutsem E, Yoshino T, Lenz HJ, Lonardi S, Falcone A, Limón ML, Saunders M, Sobrero A, Park YS, Ferreiro R, Hong YS, Tomasek J, Taniguchi H, Ciardiello F, Stoehr J, Oum'Hamed Z, Vlassak S, Studeny M, Argiles G.

Ann Oncol. 2018 Sep 1;29(9):1955-1963. doi: 10.1093/annonc/mdy241.

44.

Molecular biomarkers in gastro-esophageal cancer: recent developments, current trends and future directions.

Battaglin F, Naseem M, Puccini A, Lenz HJ.

Cancer Cell Int. 2018 Jul 11;18:99. doi: 10.1186/s12935-018-0594-z. eCollection 2018. Review.

45.

Plant organelle RNA editing and its specificity factors: enhancements of analyses and new database features in PREPACT 3.0.

Lenz H, Hein A, Knoop V.

BMC Bioinformatics. 2018 Jul 3;19(1):255. doi: 10.1186/s12859-018-2244-9.

46.

Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer.

Suenaga M, Schirripa M, Cao S, Zhang W, Yang D, Cremolini C, Lonardi S, Bergamo F, Ning Y, Yamamoto N, Okazaki S, Berger MD, Miyamoto Y, Gopez R Jr, Barzi A, Yamaguchi T, Stintzing S, Heinemann V, Loupakis F, Falcone A, Lenz HJ.

Pharmacogenomics J. 2018 Sep;18(5):623-632. doi: 10.1038/s41397-018-0030-8. Epub 2018 Jun 21.

47.

Novel Common Genetic Susceptibility Loci for Colorectal Cancer.

Schmit SL, Edlund CK, Schumacher FR, Gong J, Harrison TA, Huyghe JR, Qu C, Melas M, Van Den Berg DJ, Wang H, Tring S, Plummer SJ, Albanes D, Alonso MH, Amos CI, Anton K, Aragaki AK, Arndt V, Barry EL, Berndt SI, Bezieau S, Bien S, Bloomer A, Boehm J, Boutron-Ruault MC, Brenner H, Brezina S, Buchanan DD, Butterbach K, Caan BJ, Campbell PT, Carlson CS, Castelao JE, Chan AT, Chang-Claude J, Chanock SJ, Cheng I, Cheng YW, Chin LS, Church JM, Church T, Coetzee GA, Cotterchio M, Cruz Correa M, Curtis KR, Duggan D, Easton DF, English D, Feskens EJM, Fischer R, FitzGerald LM, Fortini BK, Fritsche LG, Fuchs CS, Gago-Dominguez M, Gala M, Gallinger SJ, Gauderman WJ, Giles GG, Giovannucci EL, Gogarten SM, Gonzalez-Villalpando C, Gonzalez-Villalpando EM, Grady WM, Greenson JK, Gsur A, Gunter M, Haiman CA, Hampe J, Harlid S, Harju JF, Hayes RB, Hofer P, Hoffmeister M, Hopper JL, Huang SC, Huerta JM, Hudson TJ, Hunter DJ, Idos GE, Iwasaki M, Jackson RD, Jacobs EJ, Jee SH, Jenkins MA, Jia WH, Jiao S, Joshi AD, Kolonel LN, Kono S, Kooperberg C, Krogh V, Kuehn T, Küry S, LaCroix A, Laurie CA, Lejbkowicz F, Lemire M, Lenz HJ, Levine D, Li CI, Li L, Lieb W, Lin Y, Lindor NM, Liu YR, Loupakis F, Lu Y, Luh F, Ma J, Mancao C, Manion FJ, Markowitz SD, Martin V, Matsuda K, Matsuo K, McDonnell KJ, McNeil CE, Milne R, Molina AJ, Mukherjee B, Murphy N, Newcomb PA, Offit K, Omichessan H, Palli D, Cotoré JPP, Pérez-Mayoral J, Pharoah PD, Potter JD, Qu C, Raskin L, Rennert G, Rennert HS, Riggs BM, Schafmayer C, Schoen RE, Sellers TA, Seminara D, Severi G, Shi W, Shibata D, Shu XO, Siegel EM, Slattery ML, Southey M, Stadler ZK, Stern MC, Stintzing S, Taverna D, Thibodeau SN, Thomas DC, Trichopoulou A, Tsugane S, Ulrich CM, van Duijnhoven FJB, van Guelpan B, Vijai J, Virtamo J, Weinstein SJ, White E, Win AK, Wolk A, Woods M, Wu AH, Wu K, Xiang YB, Yen Y, Zanke BW, Zeng YX, Zhang B, Zubair N, Kweon SS, Figueiredo JC, Zheng W, Marchand LL, Lindblom A, Moreno V, Peters U, Casey G, Hsu L, Conti DV, Gruber SB.

J Natl Cancer Inst. 2019 Feb 1;111(2):146-157. doi: 10.1093/jnci/djy099.

48.

Association Between Height and Clinical Outcome in Metastatic Colorectal Cancer Patients Enrolled Onto a Randomized Phase 3 Clinical Trial: Data From the FIRE-3 Study.

McSkane M, Stintzing S, Heinemann V, Puccini A, Naseem M, Cao S, Lenz HJ, Jelas I.

Clin Colorectal Cancer. 2018 Sep;17(3):215-222.e3. doi: 10.1016/j.clcc.2018.05.003. Epub 2018 May 10.

PMID:
29880436
49.

Identification of a Genomic Region between SLC29A1 and HSP90AB1 Associated with Risk of Bevacizumab-Induced Hypertension: CALGB 80405 (Alliance).

Li M, Mulkey F, Jiang C, O'Neil BH, Schneider BP, Shen F, Friedman PN, Momozawa Y, Kubo M, Niedzwiecki D, Hochster HS, Lenz HJ, Atkins JN, Rugo HS, Halabi S, Kelly WK, McLeod HL, Innocenti F, Ratain MJ, Venook AP, Owzar K, Kroetz DL.

Clin Cancer Res. 2018 Oct 1;24(19):4734-4744. doi: 10.1158/1078-0432.CCR-17-1523. Epub 2018 Jun 5.

PMID:
29871907
50.

Comparative Molecular Analyses of Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, and Gastric Adenocarcinoma.

Salem ME, Puccini A, Xiu J, Raghavan D, Lenz HJ, Korn WM, Shields AF, Philip PA, Marshall JL, Goldberg RM.

Oncologist. 2018 Nov;23(11):1319-1327. doi: 10.1634/theoncologist.2018-0143. Epub 2018 Jun 4.

PMID:
29866946

Supplemental Content

Support Center